For almost two decades, Kathleen Peterson has focused on delivering practical legal advice to help life sciences clients achieve their business goals while complying with complex government price reporting requirements.

Whether a company is a small biologic manufacturer preparing to launch a first product, or an established pharmaceutical manufacturer with a portfolio of marketed drugs, Kathleen assists in analyzing, explaining, and implementing complicated price reporting requirements applicable to commercial drug and biologic products, such as those under the Medicaid Drug Rebate Program, the 340B Drug Discount Program, and Medicare Part B. Kathleen also has experience analyzing fraud and abuse, managed care contracting, and Medicare Part D issues, and she has served as in-house counsel to a pharmaceutical manufacturer.

Kathleen draws on her significant cross-industry experience when reviewing detailed government pricing methodologies and assumptions, as well as when helping clients understand government pricing implications of business proposals (such as commercial discounting strategies, value-based arrangements, and patient programs). She is also a key strategic resource to life sciences companies interpreting and analyzing government drug pricing policy proposals and legislation. Kathleen is frequently sought out as a public speaker on government pricing issues and has written a number of related client publications and articles.